Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 12 of 12 entries
View as:

Study Investigating Anti-drug Antibodies in NSCLC Patients Exposed to Checkpoint Inhibitors (IMB)

Phase: N/A Priority: Normal
NCT ID: NCT06823401 Org: User:
Start: 05/20/21 End: 12/31/25 Due: 12/31/26

The Predictive Role of Programmed Death Ligand 1 (PD-L1) and Neutrophil to Lymphocyte Ratio (NLR) in Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT03816657 Org: User:
Start: 02/15/15 End: 03/30/19 Due: 03/30/20

Crizotinib in ALK Rearranged Non-small-cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04317651 Org: User:
Start: 05/16/19 End: 06/30/22 Due: 06/30/23

Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

Phase: N/A Priority: Normal
NCT ID: NCT04811001 Org: User:
Start: 06/12/20 End: 12/31/23 Due: 12/31/24

Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

Phase: N/A Priority: Normal
NCT ID: NCT04884282 Org: User:
Start: 10/12/21 End: 05/17/25 Due: 05/17/26

Prognostic Value of PD-L1 in NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT03078959 Org: User:
Start: 03/03/17 End: 04/15/17 Due: 04/15/18

Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)

Phase: N/A Priority: Normal
NCT ID: NCT03896074 Org: User:
Start: 05/31/19 End: 04/30/23 Due: 04/30/24

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

Phase: N/A Priority: Normal
NCT ID: NCT05568212 Org: User:
Start: 05/02/22 End: 04/30/25 Due: 04/30/26

CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation

Phase: N/A Priority: Normal
NCT ID: NCT03911193 Org: User:
Start: 09/21/18 End: 09/30/20 Due: 09/30/21

An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)

Phase: N/A Priority: Normal
NCT ID: NCT03823625 Org: User:
Start: 09/13/17 End: 02/28/21 Due: 02/28/22

PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03439215 Org: User:
Start: 06/13/17 End: 06/30/22 Due: 06/30/23

Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)

Phase: N/A Priority: Normal
NCT ID: NCT02499614 Org: User:
Start: 12/31/14 End: 12/31/18 Due: 12/31/19